Skip to main content
Clinical Trials/TCTR20210706003
TCTR20210706003
Not yet recruiting
Not Applicable

Comparison of 28-days mortality rate in patients with cardiogenic shock receiving between norepinephrine and dopamine.

Faculty of Pharmaceutical Sciences, Chulalongkorn University0 sites476 target enrollmentJuly 6, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients with cardiogenic shock require vasopressor agents or inotrope agents to restore and maintain blood pressure and cardiac output.
Sponsor
Faculty of Pharmaceutical Sciences, Chulalongkorn University
Enrollment
476
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2021
End Date
January 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Faculty of Pharmaceutical Sciences, Chulalongkorn University

Eligibility Criteria

Inclusion Criteria

  • Patients with cardiogenic shock who admitted to the CCU and ICCU at King Chulalongkorn Memorial Hospital between 1 January 2014 to 31 December 2021\.
  • All adults patients age greater than 18 who receieved norepinephrine or dopamine. Patients diagnosed with cardiogenic shock were identified by the presence of International Classification of Disease, tenth revision, ICD 10th code R570 in the list of diagnosed generated during the course of their hospital stay or identified by clinical criteria (SBP\< 90 mmHg despite adequate amount of fluids had been administration and if there were signs of tissue hypoperfusion (e.g. altered mental state, cold extremities, urine output of \< 0\.5 ml/kg/h or \< 30 ml/h, arterial blood pH \< 7\.35, arterial blood lactate \> 2 mmol/L or serum creatinine rising at least 0\.3 mg/dL or increasing more than 1\.5 to 1\.9 times of baseline serum creatinine) or hemodynamic criteria (e.g. cardiac index less than 2\.2 L/min/m2 and pulmonary capillary wedge pressure more than 15 mmHg) in 24 to 48 hours before received norepinephrine or dopamine.

Exclusion Criteria

  • 1\. Shock from other cause such as hypovolemic shock, sepsis shock or anaphalaxis shock in 24 to 48 hours before received norepinephrine or dopamine.
  • 2\. Patients with cardiogenic shock who recieved both norepinephrine and dopamine.

Outcomes

Primary Outcomes

Not specified

Similar Trials